Semin Reprod Med 2014; 32(04): 245-252
DOI: 10.1055/s-0034-1375176
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Food and Drug Supplements to Improve Fertility Outcomes

Bulent Urman
1   Department of Obstetrics and Gynecology, American Hospital, Istanbul, Turkey
2   Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey
Ozgur Oktem
1   Department of Obstetrics and Gynecology, American Hospital, Istanbul, Turkey
2   Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey
› Author Affiliations
Further Information

Publication History

Publication Date:
11 June 2014 (online)


Food and drug supplements (FDS) are extensively used by infertile couples either to supplement medical infertility treatment and assisted conception or as a means to independently improve conception rates. The majority of FDS are composed of antioxidants that are used for male and female infertility. Their use, despite being biologically plausible, lacks scientific support due to limitations stemming from poorly designed small studies. FDS and for that matter complementary and alternative medicine (CAM) is plagued by fallacies that confuse or mislead the public and thus may prevent many patients from making the right therapeutic decisions regarding their infertility problem. We do concur that the absence of evidence is not the evidence of absence; however, one should be wary of the apparent benign effects of FDS and CAM. The current literature seems to suggest a beneficial effect of antioxidants on male infertility. There is, however, no FDS that has been proven beyond doubt to increase conception rates in female infertility. The additive value of CAM and FDS on the success of assisted conception is also not known. Well-designed randomized studies are urgently needed given the popularity and ever increasing consumption of these supplements by the infertile couples.

  • References

  • 1 Dennehy CE. The use of herbs and dietary supplements in gynecology: an evidence-based review. J Midwifery Womens Health 2006; 51 (6) 402-409
  • 2 Eisenberg DM, Davis RB, Ettner SL , et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280 (18) 1569-1575
  • 3 Zoorob RJ, Sidani M, Williams J, Grief SN. Women's health: selected topics. Prim Care 2010; 37 (2) 367-387
  • 4 Foresta C, Bettella A, Garolla A, Ambrosini G, Ferlin A. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005; 84 (3) 654-661
  • 5 Selice R, Garolla A, Pengo M, Caretta N, Ferlin A, Foresta C. The response to FSH treatment in oligozoospermic men depends on FSH receptor gene polymorphisms. Int J Androl 2011; 34 (4) 306-312
  • 6 Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000; (2) CD000151
  • 7 Raman JD, Schlegel PN. Aromatase inhibitors for male infertility. J Urol 2002; 167 (2, Pt 1) 624-629
  • 8 Vandekerckhove P, Lilford R, Vail A, Hughes E. Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000; (2) CD000150
  • 9 Ross C, Morriss A, Khairy M , et al. A systematic review of the effect of oral antioxidants on male infertility. Reprod Biomed Online 2010; 20 (6) 711-723
  • 10 Tremellen K, Miari G, Froiland D, Thompson J. A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Aust N Z J Obstet Gynaecol 2007; 47 (3) 216-221
  • 11 Zini A, Al-Hathal N. Antioxidant therapy in male infertility: fact or fiction?. Asian J Androl 2011; 13 (3) 374-381
  • 12 Ramasamy R, Stahl PJ, Schlegel PN. Medical therapy for spermatogenic failure. Asian J Androl 2012; 14 (1) 57-60
  • 13 Zini A, San Gabriel M, Baazeem A. Antioxidants and sperm DNA damage: a clinical perspective. J Assist Reprod Genet 2009; 26 (8) 427-432
  • 14 Comhaire F, Decleer W. Quantifying the effectiveness and cost-efficiency of food supplementation with antioxidants for male infertility. Reprod Biomed Online 2011; 23 (3) 361-362
  • 15 Allison JL, Schust DJ. Recurrent first trimester pregnancy loss: revised definitions and novel causes. Curr Opin Endocrinol Diabetes Obes 2009; 16 (6) 446-450
  • 16 Gil-Villa AM, Cardona-Maya W, Agarwal A, Sharma R, Cadavid A. Role of male factor in early recurrent embryo loss: do antioxidants have any effect?. Fertil Steril 2009; 92 (2) 565-571
  • 17 Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005; 3: 28
  • 18 Lloyd KB, Hornsby LB. Complementary and alternative medications for women's health issues. Nutr Clin Pract 2009; 24 (5) 589-608
  • 19 Suzuki T, Sugino N, Fukaya T , et al. Superoxide dismutase in normal cycling human ovaries: immunohistochemical localization and characterization. Fertil Steril 1999; 72 (4) 720-726
  • 20 Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008; 295 (4) C849-C868
  • 21 Shkolnik K, Tadmor A, Ben-Dor S, Nevo N, Galiani D, Dekel N. Reactive oxygen species are indispensable in ovulation. Proc Natl Acad Sci U S A 2011; 108 (4) 1462-1467
  • 22 Park JI, Jeon HJ, Jung NK , et al. Periovulatory expression of hydrogen peroxide-induced sulfiredoxin and peroxiredoxin 2 in the rat ovary: gonadotropin regulation and potential modification. Endocrinology 2012; 153 (11) 5512-5521
  • 23 Oyawoye OA, Abdel-Gadir A, Garner A, Leonard AJ, Perrett C, Hardiman P. The interaction between follicular fluid total antioxidant capacity, infertility and early reproductive outcomes during in vitro fertilization. Redox Rep 2009; 14 (5) 205-213
  • 24 Henmi H, Endo T, Kitajima Y, Manase K, Hata H, Kudo R. Effects of ascorbic acid supplementation on serum progesterone levels in patients with a luteal phase defect. Fertil Steril 2003; 80 (2) 459-461
  • 25 Prieto L, Quesada JF, Cambero O , et al. Analysis of follicular fluid and serum markers of oxidative stress in women with infertility related to endometriosis. Fertil Steril 2012; 98 (1) 126-130
  • 26 Singh AK, Chattopadhyay R, Chakravarty B, Chaudhury K. Markers of oxidative stress in follicular fluid of women with endometriosis and tubal infertility undergoing IVF. Reprod Toxicol 2013; 42: 116-124
  • 27 Mier-Cabrera J, Aburto-Soto T, Burrola-Méndez S , et al. Women with endometriosis improved their peripheral antioxidant markers after the application of a high antioxidant diet. Reprod Biol Endocrinol 2009; 7: 54
  • 28 Griesinger G, Franke K, Kinast C , et al. Ascorbic acid supplement during luteal phase in IVF. J Assist Reprod Genet 2002; 19 (4) 164-168
  • 29 Paszkowski T, Traub AI, Robinson SY, McMaster D. Selenium dependent glutathione peroxidase activity in human follicular fluid. Clin Chim Acta 1995; 236 (2) 173-180
  • 30 Özkaya MO, Nazıroğlu M, Barak C, Berkkanoglu M. Effects of multivitamin/mineral supplementation on trace element levels in serum and follicular fluid of women undergoing in vitro fertilization (IVF). Biol Trace Elem Res 2011; 139 (1) 1-9
  • 31 Edassery SL, Shatavi SV, Kunkel JP , et al. Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Fertil Steril 2010; 94 (7) 2636-2641
  • 32 Seko LM, Moroni RM, Leitao VM , et al. Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2014; 101 (1) 154 , e4
  • 33 Bergmann J, Luft B, Boehmann S, Runnebaum B, Gerhard I. [The efficacy of the complex medication Phyto-Hypophyson L in female, hormone-related sterility. A randomized, placebo-controlled clinical double-blind study]. Forsch Komplementarmed Klass Naturheilkd 2000; 7 (4) 190-199
  • 34 Roemheld-Hamm B. Chasteberry. Am Fam Physician 2005; 72 (5) 821-824
  • 35 Westphal LM, Polan ML, Trant AS, Mooney SB. A nutritional supplement for improving fertility in women: a pilot study. J Reprod Med 2004; 49 (4) 289-293
  • 36 Westphal LM, Polan ML, Trant AS. Double-blind, placebo-controlled study of Fertilityblend: a nutritional supplement for improving fertility in women. Clin Exp Obstet Gynecol 2006; 33 (4) 205-208
  • 37 Showell MG, Brown J, Clarke J, Hart RJ. Antioxidants for female subfertility. Cochrane Database Syst Rev 2013; 8: CD007807
  • 38 Luk J, Torrealday S, Neal Perry G, Pal L. Relevance of vitamin D in reproduction. Hum Reprod 2012; 27 (10) 3015-3027
  • 39 Ott J, Wattar L, Kurz C , et al. Parameters for calcium metabolism in women with polycystic ovary syndrome who undergo clomiphene citrate stimulation: a prospective cohort study. Eur J Endocrinol 2012; 166 (5) 897-902
  • 40 Ozkan S, Jindal S, Greenseid K , et al. Replete vitamin D stores predict reproductive success following in vitro fertilization. Fertil Steril 2010; 94 (4) 1314-1319
  • 41 Aleyasin A, Aghahoseini M, Mokhtar S, Fallahi P. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients. Acta Med Iran 2011; 49 (11) 715-720
  • 42 Anifandis GM, Dafopoulos K, Messini CI , et al. Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in the IVF outcome. Reprod Biol Endocrinol 2010; 8: 91
  • 43 Ried K, Stuart K. Efficacy of traditional Chinese herbal medicine in the management of female infertility: a systematic review. Complement Ther Med 2011; 19 (6) 319-331
  • 44 Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol 2011; 9: 67
  • 45 Urman B, Yakin K. DHEA for poor responders: can treatment be justified in the absence of evidence?. Reprod Biomed Online 2012; 25 (2) 103-107
  • 46 Urman B, Yakin K. Does dehydroepiandrosterone have any benefit in fertility treatment?. Curr Opin Obstet Gynecol 2012; 24 (3) 132-135
  • 47 Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope?. Hum Reprod 2011; 26 (8) 1941-1944
  • 48 Thompson RD, Carlson M, Thompson RD, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. J AOAC Int 2000; 83 (4) 847-857
  • 49 Barad DH, Weghofer A, Gleicher N. Dehydroepiandrosterone treatment of ovarian failure. Fertil Steril 2009; 91 (5) e14 , author reply e15
  • 50 Gleicher N, Weghofer A, Barad DH. Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online 2010; 21 (3) 360-365
  • 51 Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010; 25 (10) 2496-2500
  • 52 Kolibianakis EM, Venetis CA, Tarlatzis BC. DHEA administration in poor responders. Hum Reprod 2011; 26 (3) 730-731 , author reply 731
  • 53 Kara M, Aydin T, Aran T , et al. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?. Eur J Obstet Gynecol Reprod Biol 2014; 173: 63-65
  • 54 Raja-Khan N, Stener-Victorin E, Wu X, Legro RS. The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2011; 301 (1) E1-E10